Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235839 | 0.79 | RPS6KA5 (0.38) | — | |
| SCHEMBL22822733 | 0.77 | HCAR3 (0.30) | HCAR3 | |
| SCHEMBL18806159 | 0.77 | HCAR3 (0.35) | HCAR3 | |
| SCHEMBL30592371 | 0.71 | HCAR3 (0.34) | HCAR3 | |
| SCHEMBL26632791 | 0.71 | BACE1 (0.35) | HCAR3 | |
| SCHEMBL19250468 | 0.71 | RPS6KA5 (0.42) | HCAR3 | |
| SCHEMBL15102133 | 0.70 | DGAT1 (0.38) | HTR1ADRD2HTR2A | |
| SCHEMBL18806192 | 0.70 | PIK3CB (0.39) | HCAR3 | |
| SCHEMBL17807829 | 0.70 | PDE1A (0.42) | — | |
| SCHEMBL17807736 | 0.70 | CDK2 (0.40) | HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | ADVNET PHARMA CO. LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR4, FGFR2 | HCAR3 622/4885HTR1A 3718/4885DRD2 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.